There was also no association of OS with length of time on immunotherapy prior to BRAF/MEKi, prior tumor regression from immune therapy, or use of immune checkpoint inhibitors concomitantly or upon progression on BRAF/MEKi. This evidence concerns the gene BRAF and neoplasm.